Also known as: MYC FISH, 8q24 FISH,c-myc FISH« Back to test list
Gene fusions and amplification involving the MYC gene at 8q24 are common in Burkitt lymphoma, and can occur in other B-cell non-Hodgkin lymphomas, for example, diffuse large B-cell lymphoma (DLBCL). These changes have diagnostic and prognostic implications.
The most common fusion partner for MYC is IGH, although other fusion partners are possible (for example, IGK and IGL). This test will also detect amplification of MYC.
Presence of a MYC gene fusion can be useful in diagnosing Burkitt lymphoma. In association with BCL2 and BLC6 gene fusions (see ‘double/triple hit lymphoma panel’), this gene fusion can also indicate prognosis in B-cell lymphoma with features intermediate between DLBCL and Burkitt lymphoma.
MYC amplification may be seen in myeloid or lymphoid neoplasms, and indicates advanced, drug-resistant disease.
This is an assay for non-heritable mutations. It does not raise issues of ethics or consent that are different from most other investigations ordered in the routine care of a patient.
Fluorescent in situ hybridisation (FISH) analysis, using probes to identify fusion of MYC with a number of different partner genes.
This test is usually requested by a haematologist or oncologist.
0.5 mL bone marrow in transport media, or 5-10 mL blood in lithium heparin.
To help ensure the quality of the test, a genetic test should be done with a dedicated sample whenever possible i.e. a sample collected specifically for that test rather than a sample that is used for multiple tests.
We also recommend that the patient or another adult check the labelling of request forms and sample tubes.